Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non–small-cell Lung Cancer

Immune checkpoint inhibitors (ICIs) are available for first- and further lines of treatment of patients with advanced non–small-cell lung cancer (NSCLC). These treatments are associated with adverse events called immune-related adverse events (IRAEs). The incidence, diagnosis, and treatment of IRAEs...

Full description

Saved in:

Bibliographic Details
Published in:	Clinical lung cancer Vol. 20; no. 3; pp. 201 - 207
Main Authors:	Grangeon, Mathieu, Tomasini, Pascale, Chaleat, Solene, Jeanson, Arnaud, Souquet-Bressand, Maxime, Khobta, Nataliya, Bermudez, Julien, Trigui, Youssef, Greillier, Laurent, Blanchon, Marilyne, Boucekine, Mohamed, Mascaux, Celine, Barlesi, Fabrice
Format:	Journal Article
Language:	English
Published:	United States Elsevier Inc 01-05-2019
Subjects:	Adult Aged Aged, 80 and over Antibodies, Monoclonal - therapeutic use Antineoplastic Agents, Immunological - adverse effects Antineoplastic Agents, Immunological - therapeutic use Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - epidemiology Carcinoma, Non-Small-Cell Lung - mortality Costimulatory and Inhibitory T-Cell Receptors - antagonists & inhibitors Drug-Related Side Effects and Adverse Reactions - epidemiology Drug-Related Side Effects and Adverse Reactions - mortality Female Humans Immuno-related adverse events Immunotherapy - adverse effects Immunotherapy - methods Incidence Lung Neoplasms - drug therapy Male Middle Aged Neoplasm Staging Nivolumab - therapeutic use Non-small cell lung cancer Proportional Hazards Models Response Retrospective Studies Survival Survival Analysis Response Immuno-related adverse events Survival Non-small cell lung cancer
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!